60 major regulatory filings by 2021 expected by Novartis

With 26 potential blockbusters in confirmatory development and 13 projects in clinical development across cell, gene and radioligand therapies, Swiss pharma giant Novartis (NOVN: VX) says it plans to make 60 major regulatory submissions between 2019 and 2021.

Throughout 2018, Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline. It claims. Today Novartis is holding an R&D and investor update in London which will provide deeper insights into the pipeline including the below.

Progressing cell, gene and radioligand therapy platforms with 13 therapies in clinical development, and 9 more expected to enter the clinic in 2019. The potentially foundational gene therapy AVXS101 delivers rapid, transformational and durable benefit in SMA Type 1, with regulatory approvals expected in USA, European Union and Japan in first-half 2019.